General Electric rides gene medication wave by availiable-made viral drug factories

LONDON (Reuters) - GE is raising its bet on biotechnology by the launch of prefabricated manufacturing units for producing virus-based gene & cell therapies, novel anti-Cancer disease treatments & vaccines. It aims to build on its existing expertise in biotech manufacturing by delivering a "factory-in-a-box" service specifically for viral vector-based medicine. Its Extremely -called KUBio factories are cheaper & faster to construct than traditional factories, offering GE a method to beat business for its growing life sciences business. A spokeswoman said GE was currently in talks by various possibility customers for the Fresh off-the-shelf viral vector factories. The are This time further than 700 viral vector-based therapies in clinical trials, spurring request for biologically Safebioreactors to churn out products.

Combination medication strengthens T cells in skin cancer pre-clinical research: Findings have implications for handling tumors lacking tumour suppressor gene PTEN

The research combined OX40 agonist antibody & GSK2366771. Together, the agents appear to be the cellular equivalent of stepping on the gas, revving up T cells & providing the additional strengththey necessity to further efficiently kill Cancer disease cells. PTEN loss occurs in many cancers including breast, colorectal, prostate & others. By Utilizing a genetically engineered mouse model of skin cancer, the team was enable to of spontaneously develop tumors by PTEN loss, & observe the combination medication. These results propose GSK2636771 curing could 'synergize' by OX40 agonist antibodies to augment effector functions of tumour-reactive T cells."

General Electric riding wave of gene medication

referring to General Electric Healthcare (NYSE |General Electric) is upping its bet on biotechnology by the launch of prefabricated manufacturing units for producing virus-based gene & cell therapies, novel anti-Cancer disease treatments & vaccines. Interest in such medicines, that Utilize engineered viruses to tote healthful geneticalmaterial into the cells of sick people, has soared as the premier wave of gene-fixing drugs reach the market. General Electric expects to have a $1B-a-year gene & cell medication business by 2025. Previously: Crispr sees gene medication milestone in Europe (Apr.

collected by :Lucy William